Iterum Therapeutics (ITRM) Research & Development (2017 - 2022)
Historic Research & Development for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to $5.8 million.
- Iterum Therapeutics' Research & Development rose 5775.26% to $5.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was $17.6 million, marking a year-over-year increase of 6446.04%. This contributed to the annual value of $10.5 million for FY2024, which is 7384.98% down from last year.
- According to the latest figures from Q4 2022, Iterum Therapeutics' Research & Development is $5.8 million, which was up 5775.26% from $4.4 million recorded in Q3 2022.
- In the past 5 years, Iterum Therapeutics' Research & Development registered a high of $28.1 million during Q3 2019, and its lowest value of $1.8 million during Q3 2021.
- Moreover, its 5-year median value for Research & Development was $5.4 million (2020), whereas its average is $10.4 million.
- Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 20377.99% in 2018, then tumbled by 8874.15% in 2020.
- Over the past 5 years, Iterum Therapeutics' Research & Development (Quarter) stood at $21.5 million in 2018, then dropped by 2.69% to $20.9 million in 2019, then crashed by 88.74% to $2.4 million in 2020, then soared by 57.46% to $3.7 million in 2021, then surged by 57.75% to $5.8 million in 2022.
- Its Research & Development stands at $5.8 million for Q4 2022, versus $4.4 million for Q3 2022 and $4.0 million for Q2 2022.